Sunshine Biopharma (SBFM) Common Equity (2016 - 2025)
Historic Common Equity for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $24.2 million.
- Sunshine Biopharma's Common Equity fell 335.45% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 335.45%. This contributed to the annual value of $23.5 million for FY2024, which is 1081.41% up from last year.
- Latest data reveals that Sunshine Biopharma reported Common Equity of $24.2 million as of Q3 2025, which was down 335.45% from $25.7 million recorded in Q2 2025.
- Sunshine Biopharma's Common Equity's 5-year high stood at $41.9 million during Q2 2022, with a 5-year trough of -$1.2 million in Q3 2021.
- In the last 5 years, Sunshine Biopharma's Common Equity had a median value of $22.7 million in 2025 and averaged $19.4 million.
- As far as peak fluctuations go, Sunshine Biopharma's Common Equity soared by 1011797.49% in 2022, and later crashed by 4561.36% in 2023.
- Quarter analysis of 5 years shows Sunshine Biopharma's Common Equity stood at $211662.0 in 2021, then skyrocketed by 10117.97% to $21.6 million in 2022, then decreased by 1.94% to $21.2 million in 2023, then rose by 10.81% to $23.5 million in 2024, then rose by 2.97% to $24.2 million in 2025.
- Its Common Equity stands at $24.2 million for Q3 2025, versus $25.7 million for Q2 2025 and $22.7 million for Q1 2025.